C3-carbon linked glutarimide degronimers for target protein degradation

US11992531B2 · kind B2 · utility

Assignee

• C4 THERAPEUTICS, INC.

Inventors

• Andrew J. Phillips · Arlington, US
• Christopher G. Nasveschuk · Stoneham, US
• James A. Henderson · Cambridge, US
• Yanke Liang · Belmont, US
• Minsheng He · Andover, US
• Kiel Lazarski · Cambridge, US
• Gesine Kerstin Veits · Somerville, US
• Harit U. Vora · Watertown, US

Key dates

• Filing date: Nov 30, 2020
• Grant date: May 28, 2024
• Expiry date: May 5, 2042

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.